Research programme: cytokine inhibitors - Transition Therapeutics
Alternative Names: Minozac; MW 015188WH; TT302Latest Information Update: 14 Sep 2016
At a glance
- Originator Northwestern University
- Developer Chinese Academy of Sciences; InnovatePharma; Northwestern University; Transition Therapeutics; University of California at Los Angeles
- Class Pyridazines; Small molecules
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Alzheimer's disease; Arthritis
Highest Development Phases
- No development reported Alzheimer's disease; Rheumatoid arthritis
- Discontinued Brain injuries; Multiple sclerosis; Parkinson's disease
Most Recent Events
- 31 Aug 2016 Transition Therapeutics has been acquired by OPKO Health
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)